BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
perigon
Last updated: April 16, 2026
BioVersys has initiated patient dosing for its global Phase 3 RIV-TARGET trial of BV100, a new antibiotic. This trial aims to evaluate BV100's efficacy and safety in treating patients with life-threatening bacterial infections, specifically targeting strains resistant to existing antibiotics. The success of this trial is crucial for the potential approval and commercialization of BV100, addressing a significant unmet medical need in antibiotic-resistant infections.
- The RIV-TARGET trial is a pivotal, global study designed to demonstrate the effectiveness of BV100. The drug is being tested in patients with severe bacterial infections caused by challenging pathogens. A key focus is its potential to combat antimicrobial resistance (AMR), a growing global health crisis. The trial will assess BV100's clinical outcomes compared to standard-of-care treatments, alongside its safety profile. Successful completion of this Phase 3 trial is a critical step towards regulatory submissions and potential market approval. This development signifies a hopeful advancement in the fight against drug-resistant bacteria, offering a new therapeutic option for patients with limited treatment choices. The trial's global nature ensures diverse patient populations and settings are included in the evaluation.
